Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H22N4O2 |
| Molecular Weight | 350.4143 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C=C(O)C=C4)C2=O
InChI
InChIKey=CUNDRHORZHFPLY-UHFFFAOYSA-N
InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3
| Molecular Formula | C20H22N4O2 |
| Molecular Weight | 350.4143 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
C-1311 is an imidazoacridinone analog. It is a next-generation investigational anticancer drug. It is an antitumor inhibitor of topoisomerase II and FMS-like tyrosine kinase 3 receptor. It was evaluated in phase I and II clinical trials for the treatment of various types of tumors. Mild treatment-related adverse events were thrombocytopenia, anemia, nausea, vomiting and diarrhea. Serious adverse event is neutropenia.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P06786 Gene ID: 855636.0 Gene Symbol: TOP2 Target Organism: Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) |
8.0 nM [IC50] | ||
Target ID: CHEMBL1743320 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18828924 DOI: 10.1200/jco.2008.26.15_suppl.1055 |
Primary | Unknown Approved UseUnknown |
||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
640 mg/m2 1 times / week multiple, intravenous (unknown) MTD Dose: 640 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 640 mg/m2, 1 times / week Sources: |
unhealthy n = 2 Health Status: unhealthy Condition: advanced solid tumours Sex: unknown Food Status: UNKNOWN Population Size: 2 Sources: |
DLT: neutropaenia... Dose limiting toxicities: neutropaenia (grade 4, 2 patients) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| neutropaenia | grade 4, 2 patients DLT |
640 mg/m2 1 times / week multiple, intravenous (unknown) MTD Dose: 640 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 640 mg/m2, 1 times / week Sources: |
unhealthy n = 2 Health Status: unhealthy Condition: advanced solid tumours Sex: unknown Food Status: UNKNOWN Population Size: 2 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. | 1990 Jan |
|
| Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. | 1992 Jan 24 |
|
| Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation. | 1996 Nov |
|
| Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form. | 2005 Sep 1 |
|
| Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311. | 2005 Sep-Oct |
Patents
Sample Use Guides
The initial dose was 480 mg/m2, 1 hr IV infusion on d 1, 8, and 15 of a 28 day cycle.
Route of Administration:
Intravenous
Acute treatments (3 h) of the a human tumour line (HeLa S3) revealed that cells exposed to C-1311 levels, which first induced persistent G2 arrest (0.5 ug/ml), subsequently died from this compartment, while doses exceeding these levels (1.0 ug/ml), paradoxically, did not cause the same extensive cell death.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 01:13:38 UTC 2023
by
admin
on
Thu Jul 06 01:13:38 UTC 2023
|
| Record UNII |
MZ4Y5H4OAB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID10160508
Created by
admin on Thu Jul 06 01:13:38 UTC 2023 , Edited by admin on Thu Jul 06 01:13:38 UTC 2023
|
PRIMARY | |||
|
CHEMBL338604
Created by
admin on Thu Jul 06 01:13:38 UTC 2023 , Edited by admin on Thu Jul 06 01:13:38 UTC 2023
|
PRIMARY | |||
|
645809
Created by
admin on Thu Jul 06 01:13:38 UTC 2023 , Edited by admin on Thu Jul 06 01:13:38 UTC 2023
|
PRIMARY | |||
|
C098965
Created by
admin on Thu Jul 06 01:13:38 UTC 2023 , Edited by admin on Thu Jul 06 01:13:38 UTC 2023
|
PRIMARY | |||
|
MZ4Y5H4OAB
Created by
admin on Thu Jul 06 01:13:38 UTC 2023 , Edited by admin on Thu Jul 06 01:13:38 UTC 2023
|
PRIMARY | |||
|
132127
Created by
admin on Thu Jul 06 01:13:38 UTC 2023 , Edited by admin on Thu Jul 06 01:13:38 UTC 2023
|
PRIMARY | |||
|
138154-39-9
Created by
admin on Thu Jul 06 01:13:38 UTC 2023 , Edited by admin on Thu Jul 06 01:13:38 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
time- and concentration-dependent inhibitor
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
